What is EZSCAN?

  • EZSCAN is a solution that helps identifying individuals at increased risk of diabetes or prediabetes based on the early detection of peripheral autonomic neuropathies.

  • It is an innovative screening method designed to improve the prevention and management of diabetes risk.

Small Fiber Neuropathy in Prediabetes and Diabetes

Degeneration of small nerve fibers reduces the innervation of sweat glands and impairs sudomotor function. (1)

The sweat gland function test consists of applying a small direct current to the sensor plates placed on the hands and feet.
At low voltage, the stratum corneum acts as a capacitor, leaving the sweat ducts as the only pathway for chloride (Cl⁻) ions transmission.

EZSCAN provides a metabolic risk score. This score is based on Electrochemical Skin Conductance of the hands and feet, BMI, and age. The Electrochemical Skin Conductance values for the hands and feet are the raw SUDOSCAN results.

Why Early Screening Matters

Small nerve fibers play an essential role in regulating autonomic functions such as sweating. In cases of diabetes or prediabetes, these fibers may deteriorate, leading to sudomotor dysfunction — often one of the earliest signs of a metabolic disorder. (2), (3)

Early screening is essential to slow down or prevent the onset of diabetes or prediabetes. Indeed, detecting these subtle changes at an early stage allows to:

  • Identify individuals at increased risk before clinically confirmed diabetes
  • Prevent complications such as advance neuropathy and cardiovascular disease

  • Improve clinical outcomes through appropriate medical interventions and lifestyle modifications

The EZSCAN test enables screening for the risk of prediabetes or diabetes in individuals who are unaware that they may already be prediabetic or diabetic.

EZSCAN Results Display

Degeneration of small nerve fibers reduces sweat gland innervation and impairs sudomotor function. The sweat gland function test consists of applying a low direct current to stainless steel electrodes in contact with the hands and feet. At low voltage, the stratum corneum behaves as a capacitor, leaving the sweat ducts as the primary pathway for chloride (Cl⁻) ions transport.

EZSCAN provides a metabolic risk score.

  • Between 0% and 25%: Results indicate a low level of risk. Repeat testing is recommended in one year.

  • Between 26% and 50%: Results indicate a moderate level of risk. Lifestyle modifications, including dietary and physical activity measures as advised by a physician, are recommended, with follow-up testing in 6 months.

  • Between 51% and 75%: Results indicate a high level of risk. Consultation with a specialist is recommended to investigate potential causes of small fiber neuropathy and to consider blood tests for prediabetes and diabetes screening.

  • Between 76% and 100%: Results indicate a very high level of risk. Specialist medical evaluation is recommended to determine the etiology of small fiber neuropathy and to perform appropriate blood tests for prediabetes and diabetes screening.

Healthcare professionals can immediately interpret the results and implement targeted preventive interventions.

EZSCAN: A Rapid and Non-Invasive Tool for Early Screening of Diabetes and Prediabetes

A study conducted at the Regional Hospital “Lic. Adolfo López Mateos” (Mexico) involving 1,414 participants demonstrated the effectiveness of EZSCAN for screening prediabetes and diabetes.

By assessing sudomotor function (sweat gland activity), EZSCAN showed good sensitivity (69-73%) and a high negative predictive value (82-98%), enabling early identification of individuals at risk.

The results indicate that subjects classified as having moderate or high risk had a significantly greater likelihood of being prediabetic or diabetic compared with those classified as low risk.

Following the EZSCAN test, no adverse effects were observed.

Conclusion: EZSCAN provides a simple, rapid, and
non-invasive solution for large-scale screening of diabetes and prediabetes, prior to the use of more complex and costly diagnostic tests. (4)

EZSCAN was evaluated in 200 adults at risk of diabetes.

Participants underwent an oral glucose tolerance test and a non-invasive assessment of sudomotor function (electrochemical sweat conductance measured at the hands and feet).

The results show that EZSCAN effectively identifies individuals at risk: 97% of participants with prediabetes or newly diagnosed diabetes were correctly classified as having moderate or high risk. EZSCAN scores were associated with markers of glycemia, insulin, and inflammation.

EZSCAN provides rapid, safe, and reproducible screening. It may complement traditional diagnostic tests and support diabetes prevention strategies in public health programs. (5)

Graph: AUC120 for glucose (a), insulin (b), proinsulin (c), C-peptide (d), and free fatty acids (e) according to the risk classification defined by EZSCAN.

EZSCAN Publications

(1). Gibbons et al. Capsaicin induces degeneration of cutaneous autonomic nerve fibers.Annals of Neurology. 2010;68(6):888-898.

(2). Tesfaye et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285-2293.

(3). Gabriel, R. et al. Reduction in the Risk of Peripheral Neuropathy and Lower Decrease in Kidney Function with Metformin, Linagliptin or
Their Fixed-Dose Combination Compared to Placebo in Prediabetes: A Randomized Controlled Trial. J. Clin. Med.2023,12,2035.

(4). Sanchez Hernandez et al. OE EZSCAN as a Screening Tool for Prediabetes and Diabetes in a Large Mexican Population. J Diabetes Metab 2015 6:505.

(5). Müller et al. Non-invasive screening of diabetes risk by assessing abnormalities of sudomotor function. Exp Clin Endocrinol Diabetes. 2015 Jan;123(1):34-8.

The advantage of
Neuropathy Early Detection

An innovative device for early detection and follow-up
of Autonomic and Small Fiber Neuropathy.

Simple results obtained in 3 minutes.